Cardiac Amyloidosis: Evolving Diagnosis and Management
Published: June 01, 2020
- This scientific statement is intended to inform clinical practice and facilitate management of transthyretin cardiac amyloidosis (ATTR-CM). The statement covers current diagnostic and treatment strategies while also identifying the lingering areas of uncertainty.
- ATTR-CM is a restrictive cardiomyopathy that results from the extracellular myocardial deposition of amyloid fibrils composed of the protein transthyretin (TTR).
- Readily accessible, accurate, noninvasive diagnostic tests can facilitate ATTR-CM diagnosis, and therapies have emerged to slow the progression of symptoms and improve survival.
- Commentary: Guidelines in a New Era for Cardiac Amyloidosis by Daniel P. Judge, MD
- Top Things to Know: Cardiac Amyloidosis: Evolving Diagnosis and Management
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
- 2016 Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies
- 2016 Knowledge Gaps in Cardiovascular Care of the Older Adult Population
- 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure
- 2013 ACCF/AHA Guideline for the Management of Heart Failure